Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

Institut Universitari Dexeus

Status: Completed

Conditions: Ovulation Induction; Vitrification; INFERTILITY; Fertility Preservation; Oocyte Donation

Treatments: Drug: ganirelix; Drug: gonadotropins plus GnRH antagonists

Study type: Interventional

Funder types: Other

Identifiers

NCT01645241

DEX005

Details and patient eligibility

About

The purpose of this study is to evaluate the clinical pregnancy rate per embryo transfer in oocytes recipients obtained after ovarian stimulation during the luteal phase of oocytes donors . This study will be performed in egg recipients and donors but this type of treatment is meant to be implemented in fertility preservation patients

Enrollment: 15 patients

Sex: Female

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• premenopausal women, 18-35 years old, FSH levels < 10 mIU/ml; AFC> 10
• regular cycles
• BMI < 28
• signed informed consent

Recipients:

• Infertile women eligible for oocytes donation
• BMI < 35
• Signed informed consent form

Exclusion criteria

-Polycystic ovarian syndrome, gonadotropins allergy

Recipients:

• Women eligible for oocytes donation
• BMI >35
• Uncontrolled Endocrine Pathology

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

Lutheal phase ovarian stimulation

Experimental group

Description:

Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.

Treatment:

Drug: gonadotropins plus GnRH antagonists

Drug: ganirelix